X

Trial Profile

An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta (Voxelotor)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Voxelotor (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions; Therapeutic Use
Acronyms PROSPECT
Sponsors Global Blood Therapeutics; Pfizer

Most Recent Events

26 Jun 2024 Planned End Date changed from 30 Oct 2029 to 31 Jan 2030.
26 Jun 2024 Planned primary completion date changed from 30 Oct 2029 to 31 Jan 2030.
12 Dec 2023 Initial results (n=85) presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com